首页 / 院系成果 / 成果详情页

Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature 期刊论文

编号：

42a91266-0c39-4ee3-97e7-6bb018dcc4b7
作者：

Wu, HaiDi(吴海帝)#^[1]Cao, HongYan(曹鸿雁)^[1]Song, ZiKai(宋子凯)^[1]Yang, Shuo(杨硕)^[1]Tang, MingLong(唐明龙)^[1]Liu, Yang(刘洋)^[1]Qin, Ling(秦玲)*^[1]
语种：

英文
期刊：

WORLD JOURNAL OF CLINICAL CASES ISSN：2307-8960 2019 年 7 卷 3 期 (382 - 388) ; FEB 6
收录：
关键词：

Rivaroxaban Routine coagulation monitoring Anticoagulation Bleeding Case report
摘要：

BACKGROUND
Rivaroxaban is a non-vitamin K antagonist oral anticoagulant that does not require coagulation monitoring based on current recommendations. Our goal is to explore whether routine coagulation monitoring should not be required for all patients receiving oral rivaroxaban, what relationship between routine coagulation abnormalities and bleeding, and how to deal with the above clinical situations through our case and review of the literature.
CASE SUMMARY
We report a 67-year-old woman with a history of atrial fibrillation who presented to the hospital with worsening dyspnea and cough. Based on electrocardiogram, venous compression ultrasonography, and computed tomography pulmonary angiography, the diagnosis of atrial fibrillation, deep venous thrombosis, and acute pulmonary embolism was confirmed. Her coagulation assays and renal function were normal on admission; she was not underweight, did not have a history of hemorrhagic disease, and her CHA2DS2-VAS, HAS-BLED, and simplified Pulmonary Embolism Severity Index scores were 3, 0, and 0, respectively. Oral rivaroxaban (15 mg twice daily) was administered. The following day, she presented gastrointestinal and gum bleeding, combined with coagulation abnormalities. Following cessation of rivaroxaban, her bleeding stopped and tests improved over the next 2 d. Rivaroxaban was begun again 3 d after recovery. However, she again presented with gastrointestinal and gum bleeding and the abnormal tests, and the therapy was discontinued. At 30-d follow-up after discharge, she presented normal coagulation tests without bleeding.
CONCLUSION
Although current guidelines recommend that using non-vitamin K antagonist oral anticoagulants including rivaroxaban do not require coagulation monitoring, a small number of patients may develop routine coagulation test changes and bleeding during rivaroxaban therapy, especially in the elderly. Clinicians should pay attention to these patients and further obtain evidence in practice.
推荐引用方式
GB/T 7714：

Wu Hai-Di,Cao Hong-Yan,Song Zi-Kai, et al. Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature [J].WORLD JOURNAL OF CLINICAL CASES,2019,7(3):382-388.
APA：

Wu Hai-Di,Cao Hong-Yan,Song Zi-Kai,Yang Shuo,&Qin Ling.(2019).Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature .WORLD JOURNAL OF CLINICAL CASES,7(3):382-388.
MLA：

Wu Hai-Di, et al. "Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature" .WORLD JOURNAL OF CLINICAL CASES 7,3(2019):382-388.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：96  下载次数：0

分享到：

浏览次数：96

下载次数：0

打印次数：0